Theratechnologies Inc. presented preclinical data that highlight the versatility and flexibility of the Company's SORT1+ Technology?? platform. In a poster session at the 2024 annual meeting of the American Association for Cancer Research (AACR) in San Diego, Calif., researchers reported that Theratechnologies' investigational camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer (CRC) and triple-negative breast cancer (TNBC) xenograft models.

The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads. A copy of the AACR poster, as well as a second poster presented at the conference, which reinforces existing data for the Company's lead investigational PDC sudocetaxel zendusortide (TH1902) in activating anti-PD-L1 immunotherapy tumor cell-killing in SORT+1 cancers, can be found at the Theratechnologies website. Sudocetaxel zendusortside is a first-of-its-kind sortilin receptor (SORT1)-targeting PDC, and the first compound to emerge from the Company's broader licensed oncology platform.

A new chemical entity, sudocetaxel z endusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted Fast Track designation to sudocetaxel z Endusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy. Sudocetaxel Zendusortide is currently being evaluated in a Phase 1 clinical trial.

Theratechnologies has established the SORT1+ TechnologyTM platform as an engine for the development of PDCs that target SORT1, which is expressed in multiple tumor types. These assumptions include, without limitation, that the Company's Phase 1 clinical trial using sudocetaxel zENDusortide will be successful, that signs of efficacy will be observed in such Phase 1 clinical trial and no toward side effects will be reported, and that the findings observed from the preclinical work conducted on new PDCs will be replicated into human subjects. These risks and uncertainties include, but are not limited to, the lack of observation of strong efficacy results from the Phase 1 clinical trial.

Therateschnologies has established the Sort1+ TechnologyTM platform as a engine for the development of P DCs that target SORT1.